Clinical trials

We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients

Clinical trials

Cancer

MiniRaP-00

Prostate cancer

A feasibility study of the repurposing of prazosin to improve treatment outcomes in men receiving radiotherapy for prostate cancer (MiniRaP-00).

Cancer

Fortitude 102

Gastric cancer

A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression

Cancer

BREAKWATER C4221015

Metastatic colorectal cancer

A Study of Encorafenib Plus Cetuximab with or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Cancer

Ascent 03 GS-US-592-6238

Breast cancer

A randomized, open-label, phase 3 study of sacituzumab govitecan versus treatment of physician's choice in patients with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express PD-L1 or in patients previously treated with anti-PD-(L)1 agents in the early setting whose tumors do express PD-L1

Cancer

ASCENT 04 - GS-US-592-6173

Breast cancer

Study of sacituzumab govitecan-hziy and pembrolizumab versus treatment of physician's choice and pembrolizumab in patients with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer.

Cancer

SHERLOCK Protocol number: CTC 0377 / TOGA 21/011

Lung cancer

Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation.

Cancer

PACIFIC-9: D9078C00001

Lung cancer

This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic cancer.

Cancer

Amplia AMP945-PC-201

Pancreatic cancer

A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients (AMP945-PC-201)

Cancer

DESTINY-Breast06

Breast cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Cancer

FUSION FPI-1966-101

Cancer

This is a first-in-human, Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, dosimetry, biodistribution, and PK of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab and the preliminary anti-tumour activity of [225Ac]-FPI-1966 in participants with FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumours. Phase 1 consists of five multiple dose escalation cohorts. Phase 2 consists of two tumour-specific cohorts and one basket cohort.

Cancer

Protocol : GS-US-587-6156

Colorectal cancer

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Cancer

ProstACT-TARGET

Prostate cancer

A Single Arm Trial of External Beam Radiation Therapy (EBRT) in Combination with 177Lu-DOTA-TLX591 Theranostic in Patients with Biochemically Recurrent, Oligometastatic, Prostate Specific Membrane Antigen- Expressing Prostate Cancer

Cancer

KEYNOTE-C93

Cancer

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

Cancer

THIO-101

Non-Small Cell Lung Cancer

A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Cancer

EpimAb - EMB09X101

Cancer

A First-in-human, Phase I Trial of study drug, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients with Advanced or metastatic Solid Tumours

Cancer

KEYNOTE-867

Cancer

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Breast Cancer

TABITHA

Breast cancer

A study to develop a prospective multi-site registry to evaluate clinical features, types of treatment, outcomes and survival in participants with HER2 positive metastatic breast cancer managed in routine practice in Australia.

Heart Disease

Vantage IDE

Cardiovascular disease

To evaluate the efficacy and safety of a new valve in patients with severe, symptomatic aortic stenosis.

Heart Disease

AngelMed (Enrolment opening soon)

Cardiovascular Disease

To evaluate a new device in patients with prior acute coronary syndrome.

Heart Disease

Arrowhead

Cardiovascular Disease

To evaluate the efficacy and safety on a new drug in participants with Mixed Dyslipidaemia.

Genitourinary Cancer

SAMETA (D5086C00001)

Genitourinary cancer

A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma)

Cancer

ICP-CL-003030

Cancer

A multi-center open-label, phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ICP-192 in patients with advanced solid tumours and FGFR gene alterations

Prostate Cancer

DECREASE

Prostate cancer

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer detected by PSMA.

Heart Disease

RO-CARDIAC

Heart disease

Can Coronary Artery Calcium Score identified on thoracic planning ct scans be used and actioned to identify patients at high risk of cardiac events: a feasibility study in patients with cancer undergoing radiotherapy (ro-cardiac)

Colorectal Cancer

AMGEN 20190172

Colorectal cancer

A Phase 3 Multicenter, Randomized, Open-label,Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation

Cancer

AMGEN 20190135

Basket – Solid Tumours

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects With Advanced Solid Tumours With KRAS p.G12C Mutation

Heart Disease

Victorion Plaque

Cardiovascular Disease, Heart Disease

Heart Disease

Victorion-2 Prevent

Heart Disease, Cardiovascular Disease

To evaluate the impact of a new medication on participants who have established cardiovascular disease and who have had a major adverse cardiovascular event.

Prostate Cancer

CONTACT-02

Prostate cancer

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Pro

Breast Cancer

DESTINY-12

Breast cancer

An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)

Lung Cancer

KRYSTAL-12

Lung cancer

A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation.

Skin Cancer

Oncobeta EPIC-SKIN (OB-RHSCT-101)

Skin cancer

Efficacy of Personalised Irradiation with Rhenium-SCT Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV, multi-centre, international, open label, single arm study

Prostate Cancer

RADIANT

Prostate cancer

A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH.

Liver Cancer

SYS-CAPLIOX (AV-LIVPIBII-01)

Liver cancer

The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.

Breast Cancer

HER2 REAL (D9673R00005)

Breast cancer

A Multicountry, Multicentre, Noninterventional Retrospective Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer.

Colorectal Cancer

SEAMARK – C4221022

Colorectal cancer

The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer.

Prostate Cancer

Prostact-Select

Prostate cancer

Safety, tolerability, biodistribution, dosimetry and efficacy study of 177Lu-DOTA-TLX591-CHO with best standard of care in patients with PSMA expressing metastatic castration-resistant prostate cancer.

Heart Disease

IONIS

Cardiovascular disease

To evaluate a new medication for the treatment of patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM).

Heart Disease

HighFLO

Heart failure

To evaluate a new mitral valve replacement in patients who moderate-severe or severe mitral regurgitation at a high surgical risk.

Heart Disease

FINEARTS-HF

Heart failure

To evaluate the efficacy and safety of a new drug on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥40% (LVEF ≥40%).

Heart Disease

ZEUS

Cardiovascular disease

To evaluate if treatment with a new drug reduces the risk cardiovascular disease in patients with established cardiovascular disease, chronic kidney disease and inflammation.

Heart Disease

CATALYST

Atrial fibrillation

Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants.

Breast Cancer

AUS-PREDICT

Breast cancer

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy.

Heart Disease

VFAHF

Heart failure

To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.

Prostate Cancer

DASL-HiCaP

Prostate cancer

The purpose of this study is to see if a new drug, darolutamide, combined with the current best treatments, can improve outcomes for people with prostate cancer.

Cancer

DYNAMIC-III

Bowel cancer

The aim of this study is to compare treatment informed by ctDNA results to standard care in patients with stage III colon cancer.

Prostate Cancer

CUPID

Prostate cancer

This study will consist of four groups with the initial three groups undergoing dose escalation and the fourth group will be to confirm the optimal dose and imaging conditions.

Lung Cancer

AdvanTIG – BGB-A317-A1217-302

Non-small cell lung cancer

The purpose of the study is to compare progression-free survival between Arm A and Arm B as assessed by investigators according to Response Evaluation Criteria in Solid Tumors Version 1.1.

Prostate Cancer

NINJA

Prostate cancer

The NINJA clinical trial aims to compare two emerging schedules of radiotherapy in the treatment of prostate cancer.

Prostate Cancer

ARANOTE

Prostate cancer

This study will assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Pancreatic Cancer

MASTERPLAN

Pancreatic cancer

This is a prospective, multicentre randomised, phase II clinical trial, with randomisation 2:1 by minimisation and stratification by tumour stage, planned chemotherapy and institution.

Bladder Cancer

Checkmate-078

Bladder cancer

A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC.

Bladder Cancer

BCG + MMC

Bladder cancer

Adding mitomycin C to BCF as adjuvant intravesical therapy for high-risk, non muscle invasive bladder cancer, a randomised phase 3 trial.

Bladder Cancer

KEYPAD

Metastatic kidney cancer

This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

Cancer

DREAM3R

Mesothelioma

The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with MPM.

Skin Cancer

GENTLER

Skin cancer

The purpose of this trial is to see if a reduced radiotherapy can deliver equivalent treatment response to full dose radiotherapy for patients with skin cancer.

Skin Cancer

BFSCT

Skin cancer

This study aims to clinically validate use of the Baker Skin Field Cancerisation Tool (BSFCT) in people attending St Vincent’s Hospital Melbourne dermatology clinic.

Cancer

KEYNOTE-992

Bladder cancer

Assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC).

CUPisco

Cancer

Phase II targeted therapy or immunotherapy guided by genomic profiling versus platinum based chemotherapy (3C) (after receiving three cycles of platinum based chemotherapy).

Breast Cancer

AVATAR

Breast cancer

Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR).

Breast Cancer

DESTINY-Breast05

Breast cancer

This study will examine the efficacy and safety of trastuzumab deruxtecan compared with trastuzumab emtansine in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

Skin Cancer

CPOST

Skin cancer

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma.

Prostate Cancer

PRIMORDIUM

Prostate cancer

The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.

Breast Cancer

CONCERTO

Breast cancer

A comparison of two routinely used skin treatments for women with breast cancer undergoing radiation therapy.

Lung Cancer

B8011011

Carcinoma, non-small-cell lung

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC).

Non-Melanoma Skin Cancer

EVOLVE

Non-melanoma Skin Cancer

Evaluation of Oedema and lymphatic function following volumetric modulated arc therapy for non-melanoma extensive skin field cancerisation of the lower limbs.

Prostate Cancer

Telix ENHANCING

Prostate cancer

The purpose of this study is to determine the effect of androgen deprivation therapy, a treatment commonly prescribed in prostate cancer patients, on the effectiveness of medical imaging techniques.

Cancer

CHALLENGE

Colon cancer

A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High-Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial.

Cancer

ADAPT-MRL

Any cancer

A Long-Term, Prospective and Retrospective, Observational Registry Assessing Technical Data and Clinical Outcomes Following Treatment with MR-Linac.

Lung Cancer

MERMAID-1

Carcinoma, non-small cell lung

The purpose of this study is to assess the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

Prostate Cancer

PROPELLER

Prostate cancer

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

Lung Cancer

MERMAID-2

Carcinoma, non-small cell lung

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Prostate Cancer

ENZA-p

Prostate cancer

Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

Dupuytren's Disease

DEPART

Connective tissue disorders

GenesisCare is recruiting patients with Dupuytren’s Disease for a research study called ‘DEPART’.

Heart Disease

PORTICO-NG

Aortic valve stenosis

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk.

Heart Disease

SUCCOUR MRI SUB-STUDY

Heart failure

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy.

Heart Disease

HighLife

Heart failure

To evaluate a new valve in patients with moderate-severe or severe mitral regurgitation and at high surgical risk.

NDROR

Skin registry

To collect data to evaluate specified outcomes for patients undergoing radiotherapy for skin cancer and inflammatory skin conditions.

Clinical Trial

EXPERT

Breast cancer

A unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.